Charles Schwab Investment Management Inc. Purchases 249,412 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Charles Schwab Investment Management Inc. raised its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 11.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,401,533 shares of the biotechnology company's stock after buying an additional 249,412 shares during the period. Charles Schwab Investment Management Inc. owned about 1.03% of ADMA Biologics worth $48,007,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ADMA. USA Financial Formulas lifted its stake in shares of ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after purchasing an additional 539 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in shares of ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock valued at $273,000 after purchasing an additional 888 shares during the last quarter. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at $30,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of ADMA Biologics by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock valued at $163,000 after purchasing an additional 1,509 shares during the last quarter. Finally, Chartwell Investment Partners LLC lifted its stake in shares of ADMA Biologics by 0.8% in the 3rd quarter. Chartwell Investment Partners LLC now owns 249,779 shares of the biotechnology company's stock valued at $4,993,000 after purchasing an additional 2,038 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

Analyst Ratings Changes

ADMA has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright upped their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Finally, Raymond James upped their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th.

ADMA Biologics Price Performance

Shares of ADMA traded down $0.42 on Monday, hitting $19.69. The company's stock had a trading volume of 6,094,748 shares, compared to its average volume of 3,633,505. The company has a market capitalization of $4.65 billion, a PE ratio of 70.32 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The company has a 50 day moving average price of $19.07 and a 200 day moving average price of $15.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the prior year, the business earned $0.01 EPS. On average, research analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.70% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.